Claudin 18.2 (CLDN18.2) is specifically expressed in highly differentiated normal gastric mucosa, but also in gastric and pancreatic cancer. Due to the tight adhesion between cells, it is very difficult for antibody drugs to bind to normal tissues. However, the loose structure of the interstitial space of cancer cells makes CLDN18.2 possible to be exposed to macromolecular protein drugs, so CLDN18.2 is an ideal target for a new generation of anti-tumor therapy. DR30303 is a fusion protein composed of single domain antibody and human Fc and specifically recognizes the of CLDN18.2. It has a killing effect on CLDN18.2 positive tumor cells through ADCC and CDC. At the same time, due to the characteristics of the target, it also reduces the toxicity to normal CLDN18.2 positive tissues. It is intended to be used in the treatment of gastric cancer and other solid tumors with abnormal expression of CLDN18.2.
DR30206 is designed as a tri-specific antibody of anti-PDL1/VEGF /TGF-β based on MultipleBody® platform. it can simultaneously antagonize three targets: PDL1, VEGF and TGF-β, has dual effects of inhibiting neovascularization and relieving immunosuppression. It is intended to be used in the treatment of diverse solid tumors.
DR30303 is composed of an anti-Claudin 18.2 single-domain antibody, an anti-HSA single-domain antibody and an anti-CD3ε scFv. DR30303 is optimized for the Immune synapse formation between T cells and tumor cells through this structure, and improve the killing efficiency. An long-acting unit is introduced to extend PK and improved the efficacy in vivo.
The synthesized GLP-1R / GIPR dual agonist is coupled with fatty acid chain. The proportion of GLP-1R and GIPR activity is the best after a lot of screening. In preclinical animal experiments, DR10627 showed extremely significant hypoglycemic and weight-loss effects. Indications include diabetes, obesity and other metabolic diseases.
DR10628 is a fatty acid-modified antidiabetic polypeptide with GLP-1R/GIPR agonistic activity，potentially used for the treatment of NASH and Type 2 diabetes.
Based on the Multiplebody ® platform, DR10624 is designed as a tri- activity human Fc fusion protein，characterized by GLP-1 / GCG dual activity and FGF21 activity. DR10624 is expected for the treatment of metabolic diseases such as diabetes, obesity and nonalcoholic fatty liver (NASH).
DR30121 is developed as an ultra-long acting anti-VEGF / Ang-2 dual antagonist for angiogenic ophthalmic diseases such as AMD and DMD based on the multiplebody ® and xlongylation ® platform. VEGF binding region and angiopoietin-2 (Ang-2) binding region were fused in the N-terminal and C-terminal of human Fc respectively. In order to further increase the hydration radius, another xlong ® sequence was introduced in the N-terminal of VEGF binding region, which give DR30121 an extra-long vitreous half-life.